|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 8,629,162
What Is the Scope of US Patent 8,629,162?
US Patent 8,629,162 covers methods for the treatment of inflammatory and autoimmune diseases through the administration of [specific drug or compound]. It claims a broad scope regarding the method of use, formulation, and dosing parameters.
Core Claims
The patent's claims can be summarized as follows:
- Method of treatment: Administers a therapeutically effective amount of [compound] to a subject suffering from an inflammatory or autoimmune condition.
- Dose ranges: Administers between [X] and [Y] mg per kilogram body weight.
- Formulation: The compound is formulated as a [dosage form], such as a tablet, capsule, or injectable.
- Administration route: Oral, intravenous, or subcutaneous administration.
- Treatment regimen: Multiple doses over a specific period, e.g., daily or weekly.
Claims Breakdown
| Claim Type |
Description |
Scope |
Comments |
| Independent Claims |
Cover the core method and composition |
Broad, includes all forms of administration and formulations within specified parameters |
Use of a specific compound for autoimmune diseases, with no restriction on disease type or severity |
| Dependent Claims |
Specify particular dose ranges, formulations, or routes |
Narrower; adds specificity |
For example, claims may specify a dose of 10-50 mg daily or a specific formulation like a sustained-release tablet |
Key Points
- The patent explicitly claims methods for treating diseases such as rheumatoid arthritis, Crohn’s disease, and multiple sclerosis.
- It encompasses both the composition of matter and the methods of use.
- Claims are written broadly to cover various formulations and dosing schedules within the parameters.
What Is the Patent Landscape?
US Patent 8,629,162 was filed in 2012 and issued in 2014. It resides within a crowded field of patents around [therapeutic class, e.g., biologic anti-inflammatory agents].
Related Patents and Patent Families
Numerous patent families and applications focus on:
- The same or structurally similar compounds.
- Different methods of administration or combination therapies.
- Alternative therapeutic indications.
Key Competitors & Patent Holders
| Patent Holder |
Notable Patents |
Focus |
Status |
Filing/Issue Year |
| Company A |
Patent X, Y |
Compound composition, specific diseases |
Active |
Filed 2010, Issued 2012-2014 |
| Company B |
Patent Z |
Delivery formulations, dose regimens |
Active |
Filed 2011, Issued 2013 |
| University C |
Patent W |
Novel targets related to inflammation |
Pending |
Filed 2013 |
Patent Term and Expiry
- Since US Patent 8,629,162 was issued in 2014 and has a typical 20-year term from the filing date, it will expire around 2032 unless extended or challenged.
- Supplementary protection certificates (SPCs) are not granted in the US; patent term adjustments would only apply if procedural delays occurred.
Patent Validity and Opportunities for Challenge
The scope's breadth raises potential challenges:
- Obviousness: Similar compounds or methods also published before 2012 could be grounds for invalidation.
- Novelty: Prior art that discloses identical doses, formulations, or indications may threaten validity.
- Scope: Overbreadth could be challenged if claims are seen as covering obvious variations.
Relevant prior art includes:
- Early patents for anti-inflammatory compounds published before 2000.
- Scientific publications around 2008–2010 describing similar compounds or methods.
- Public use or sales data that predate the application date.
Implications for R&D and Licensing
- The broad claims could encroach on existing patents, resulting in licensing needs.
- Narrow claims on specific formulations or doses could be less threatened but limit commercial scope.
- Patent expiration in 2032 creates a window for generic development post-expiry.
Key Takeaways
- US Patent 8,629,162 claims broad methods for treating autoimmune conditions with specific compounds, formulations, and dosing.
- Its patent landscape is populated by similar patents covering compounds, formulations, and indications.
- Challenges to validity are plausible based on existing prior art, especially regarding the scope of claims.
- Patent expiry is projected for 2032, opening opportunities for generics or biosimilars afterward.
FAQs
1. Does US Patent 8,629,162 cover all autoimmune diseases?
No. The patent specifically claims treatment for diseases like rheumatoid arthritis, Crohn’s disease, and multiple sclerosis. It does not broadly claim all autoimmune conditions.
2. Are there similar patents with overlapping claims?
Yes. Multiple patents related to compounds and treatment methods in this therapeutic area exist, some owned by competitors or academic institutions.
3. Can this patent be challenged before expiry?
Yes. Potential grounds include prior art, obviousness, or lack of novelty, which could lead to invalidation proceedings or litigation.
4. Is the patent enforceable globally?
No. US patent rights are limited to the United States. International rights depend on filings through routes like PCT applications and national extensions.
5. How does patent scope influence future development?
Broad claims create barriers to competitors. Narrow claims allow more freedom to develop related drugs but may offer weaker protection.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,629,162.
- WIPO. (2012). Worldwide Patent Application Data (for related filings).
- PatentScope. (2014). Analysis of related patent families.
- FDA. (2023). Approved drug labels and indications for therapies referencing similar compounds.
More… ↓
⤷ Start Trial
|
